The Jin Pharmaceutical Group might have been paying close attention, but the two scientists were extremely busy and had very high standards. As far as they were concerned, a single paper in a special issue of *Cell*—which was merely a superficial overview of a conceptual new drug called "Fengmu Tiada"—wasn't enough to warrant a meeting with Wu Ting.
After all, Wu Ting had no background in pharmacology. He was a clinician—a surgeon—a complete outsider to the world of pharmaceutical R&D. So, even with Deng Feifei pulling strings for him, the two scientists wouldn't give him the time of day.
In their eyes, a pointless conversation with Wu Ting was a waste of time that could be better spent conducting more clinical trials.
With Jin Yihong's full support and trust, their R&D teams had already invested a great deal of funding and time. Jia Jun's team, in particular, was on the verge of bringing their new drug to market and couldn't afford to waste a single moment.
